Monaco Asset Management SAM Has $2.29 Million Stake in Novavax, Inc. (NASDAQ:NVAX)

Monaco Asset Management SAM raised its position in Novavax, Inc. (NASDAQ:NVAX) by 356.0% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 285,000 shares of the biopharmaceutical company’s stock after purchasing an additional 222,500 shares during the period. Novavax accounts for approximately 0.3% of Monaco Asset Management SAM’s portfolio, making the stock its 28th largest position. Monaco Asset Management SAM owned 0.18% of Novavax worth $2,291,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. E Fund Management Co. Ltd. lifted its position in shares of Novavax by 5.1% in the 4th quarter. E Fund Management Co. Ltd. now owns 25,340 shares of the biopharmaceutical company’s stock worth $204,000 after purchasing an additional 1,219 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Novavax by 0.4% during the 4th quarter. Bank of New York Mellon Corp now owns 436,451 shares of the biopharmaceutical company’s stock worth $3,509,000 after buying an additional 1,664 shares in the last quarter. Victory Capital Management Inc. boosted its holdings in shares of Novavax by 12.0% during the 3rd quarter. Victory Capital Management Inc. now owns 19,292 shares of the biopharmaceutical company’s stock worth $244,000 after buying an additional 2,072 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Novavax by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 33,965 shares of the biopharmaceutical company’s stock worth $273,000 after buying an additional 3,174 shares in the last quarter. Finally, Commonwealth Equity Services LLC boosted its holdings in shares of Novavax by 8.1% during the 4th quarter. Commonwealth Equity Services LLC now owns 43,034 shares of the biopharmaceutical company’s stock worth $346,000 after buying an additional 3,236 shares in the last quarter. Institutional investors and hedge funds own 53.04% of the company’s stock.

Novavax Stock Performance

Shares of NVAX opened at $8.17 on Friday. The stock has a 50 day moving average price of $8.45 and a two-hundred day moving average price of $9.69. The firm has a market capitalization of $1.31 billion, a P/E ratio of -3.62, a P/E/G ratio of 2.85 and a beta of 2.92. Novavax, Inc. has a 52 week low of $3.81 and a 52 week high of $23.86.

Novavax (NASDAQ:NVAX) last issued its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.51) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.24. The company had revenue of $88.31 million for the quarter, compared to the consensus estimate of $85.48 million. During the same period in the prior year, the firm posted ($1.44) earnings per share. On average, equities analysts forecast that Novavax, Inc. will post -1.46 earnings per share for the current year.

Analyst Ratings Changes

NVAX has been the topic of a number of research analyst reports. BTIG Research initiated coverage on Novavax in a report on Friday, February 28th. They set a “buy” rating and a $19.00 price target on the stock. HC Wainwright reissued a “buy” rating and issued a $19.00 price objective on shares of Novavax in a research note on Tuesday, December 10th. Finally, TD Cowen raised Novavax to a “hold” rating in a research note on Thursday, February 27th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $18.00.

Insider Buying and Selling at Novavax

In other Novavax news, Director James F. Young sold 5,400 shares of the stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $8.00, for a total value of $43,200.00. Following the completion of the sale, the director now owns 51,760 shares in the company, valued at approximately $414,080. This trade represents a 9.45 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 1.00% of the company’s stock.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.